Mafosfamide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mafosfamide
Accession Number
DB12083
Type
Small Molecule
Groups
Investigational
Description

Mafosfamide has been used in trials studying the treatment of Lymphoma, Leukemia, Meningeal Neoplasm, and Brain and Central Nervous System Tumors.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
5970HH9923
CAS number
88859-04-5
Weight
Average: 401.25
Monoisotopic: 399.9850065
Chemical Formula
C9H19Cl2N2O5PS2
InChI Key
PBUUPFTVAPUWDE-UGZDLDLSSA-N
InChI
InChI=1S/C9H19Cl2N2O5PS2/c10-2-4-13(5-3-11)19(14)12-9(1-6-18-19)20-7-8-21(15,16)17/h9H,1-8H2,(H,12,14)(H,15,16,17)/t9-,19-/m0/s1
IUPAC Name
2-{[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl}ethane-1-sulfonic acid
SMILES
OS(=O)(=O)CCS[[email protected]]1CCO[[email protected]@](=O)(N1)N(CCCl)CCCl

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mafosfamide.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Mafosfamide.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Mafosfamide.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mafosfamide.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mafosfamide.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Mafosfamide.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mafosfamide.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mafosfamide.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Mafosfamide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mafosfamide.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Mafosfamide.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Mafosfamide.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Mafosfamide.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Mafosfamide.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Mafosfamide.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mafosfamide.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Mafosfamide.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Mafosfamide.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Mafosfamide.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
76968809
PubChem Substance
347828389
ChemSpider
32697788

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Meningeal Neoplasms1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.54 mg/mLALOGPS
logP-0.61ALOGPS
logP-0.83ChemAxon
logS-1.9ALOGPS
pKa (Strongest Acidic)-0.9ChemAxon
pKa (Strongest Basic)0.057ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity84.86 m3·mol-1ChemAxon
Polarizability36.04 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as nitrogen mustard compounds. These are compounds having two beta-haloalkyl groups bound to a nitrogen atom.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Nitrogen mustard compounds
Direct Parent
Nitrogen mustard compounds
Alternative Parents
Phosphoric monoester diamides / Oxazaphosphinanes / Sulfonyls / Organosulfonic acids / Alkanesulfonic acids / Sulfenyl compounds / Oxacyclic compounds / Dialkylthioethers / Azacyclic compounds / Organopnictogen compounds
show 5 more
Substituents
Nitrogen mustard / Phosphoric monoester diamide / Organic phosphoric acid derivative / Oxazaphosphinane / Organic phosphoric acid amide / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Organosulfonic acid / Sulfonyl / Alkanesulfonic acid
show 17 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:19 / Updated on November 09, 2017 05:01